Seeking Alpha

ProPhase Labs Announces Successful Study Demonstrating Performance of BE-Smart™ Test in Detecting Esophageal Cancer

BE-Smart represents a significant advance in diagnosis and management of Esophageal disease that affects an estimated 60 million people in the United States Study shows >95% success rate, validating ...
WJHL-TV

ProPhase Labs’ Linebacker-1 Cancer Therapeutic shows promising mechanisms of action as both a mono-therapy and co-therapy in preclinical studies attacking a range of hard-to ...

Garden City, NY, May 03, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a next-generation biotech, genomics and diagnostics company, today provided an update regarding its ...
Seeking Alpha

ProPhase Labs Announces Plans for Major Expansion of its Pharmaloz Manufacturing, Inc. Subsidiary to Meet Growing Demand

Garden City, NY, Feb. 15, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (PRPH) (“ProPhase”), a growth oriented and diversified diagnostics, genomics and biotech company, today provided a business ...
Nasdaq

ProPhase Labs Inc. Validates BE-Smart™ Diagnostic Test for Esophageal Disease with Over 95% Success Rate

ProPhase Labs announces BE-Smart's validation for esophageal disease diagnostics, achieving over 95% success in detecting critical biomarkers. ProPhase Labs Inc. announced the successful validation of ...
Nasdaq

ProPhase Labs (NASDAQ:PRPH) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' So it might ...